Abilify

Drug: Abilify
Company: Bristol-Myers Squibb
Total spend Q1, 2012: $35.9 million
Total spend Q1, 2011: $29.7 million
Watch the TV commercial here >>

While it got itself into trouble early with this atypical antipsychotic, in the long run it has paid off handsomely for Bristol-Myers Squibb ($BMY). Abilify placed third in drugs.com's first-quarter ranking of top selling drugs at $1.34 billion. Pretty impressive since sales in all of last year were $2.8 billion, suggesting that the advertising is paying off. It has not always been smooth sailing on this product. Abilify was the focus of the company's 2007, $515 million settlement agreement with the Justice Department, which said the company targeted sales at dementia patients and adolescents, in whom use was unapproved at the time. Bristol-Myers licenses the drug from Japan's Otsuka Pharmaceutical and has patent protection in the U.S. into 2015.

Abilify
Read more on

Suggested Articles

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.